Johnson FM - Search Results

1

Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma.

Brooks HD, Glisson BS, Bekele BN, Johnson FM, Ginsberg LE, El-Naggar A, Culotta KS, Takebe N, Wright J, Tran HT, Papadimitrakopoulou VA. Brooks HD, et al. Among authors: johnson fm. Cancer. 2011 May 15;117(10):2112-9. doi: 10.1002/cncr.25769. Epub 2010 Nov 29. Cancer. 2011. PMID: 21523723 Free PMC article. Clinical Trial.

2

Alterations in taste sensation: a case presentation of a patient with end-stage pancreatic cancer.

Johnson FM. Johnson FM. Cancer Nurs. 2001 Apr;24(2):149-55. doi: 10.1097/00002820-200104000-00011. Cancer Nurs. 2001. PMID: 11318263 Review.

3

Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer.

Johnson FM, Kurie JM, Peeples BO, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Johnson FM, et al. Oncology (Williston Park). 2003 Jul;17(7 Suppl 7):17-21. Oncology (Williston Park). 2003. PMID: 12886869 Clinical Trial.

4

Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.

Johnson FM, Kurie JM, Peeples BO, Lee JJ, Feng L, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Johnson FM, et al. Clin Lung Cancer. 2003 Jul;5(1):40-5. doi: 10.3816/CLC.2003.n.020. Clin Lung Cancer. 2003. PMID: 14596703 Clinical Trial.

5

A Phase II study of docetaxel and carboplatin as neoadjuvant therapy for nasopharyngeal carcinoma with early T status and advanced N status.

Johnson FM, Garden A, Palmer JL, Kies M, Clayman G, Brumfield B, Khuri FR, Morrison W, Papadimitrakopoulou V, Diaz EM, Glisson BS. Johnson FM, et al. Cancer. 2004 Mar 1;100(5):991-8. doi: 10.1002/cncr.20079. Cancer. 2004. PMID: 14983495 Free article. Clinical Trial.

6

Cyclooxygenase-2 induction and prostaglandin E2 accumulation in squamous cell carcinoma as a consequence of epidermal growth factor receptor activation by imatinib mesylate.

Johnson FM, Yang P, Newman RA, Donato NJ. Johnson FM, et al. J Exp Ther Oncol. 2004 Dec;4(4):317-25. J Exp Ther Oncol. 2004. PMID: 15844661

7

Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.

Johnson FM, Saigal B, Donato NJ. Johnson FM, et al. J Cell Physiol. 2005 Nov;205(2):218-27. doi: 10.1002/jcp.20383. J Cell Physiol. 2005. PMID: 15887238

8

A phase I/II study of neoadjuvant chemotherapy followed by radiation with boost chemotherapy for advanced T-stage nasopharyngeal carcinoma.

Johnson FM, Garden AS, Palmer JL, Shin DM, Morrison W, Papadimitrakopoulou V, Khuri F, Clayman G, Goepfert H, Ang KK, Hong WK, Glisson BS. Johnson FM, et al. Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):717-24. doi: 10.1016/j.ijrobp.2005.03.001. Int J Radiat Oncol Biol Phys. 2005. PMID: 16199307 Clinical Trial.

9

Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.

Johnson FM, Saigal B, Talpaz M, Donato NJ. Johnson FM, et al. Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6924-32. doi: 10.1158/1078-0432.CCR-05-0757. Clin Cancer Res. 2005. PMID: 16203784

10

Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma.

Johnson FM, Krug LM, Tran HT, Shoaf S, Prieto VG, Tamboli P, Peeples B, Patel J, Glisson BS. Johnson FM, et al. Cancer. 2006 Jan 15;106(2):366-74. doi: 10.1002/cncr.21640. Cancer. 2006. PMID: 16342249 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

210 results

Search Page

Filters